Whipplewood Advisors LLC Buys New Shares in Koninklijke Philips (NYSE:PHG)

Whipplewood Advisors LLC bought a new stake in Koninklijke Philips (NYSE:PHG) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 2,160 shares of the technology company’s stock, valued at approximately $55,000.

Several other hedge funds have also made changes to their positions in the stock. Wilmington Savings Fund Society FSB bought a new position in Koninklijke Philips during the third quarter worth about $54,000. Allworth Financial LP raised its stake in shares of Koninklijke Philips by 24.9% in the fourth quarter. Allworth Financial LP now owns 3,993 shares of the technology company’s stock valued at $105,000 after acquiring an additional 797 shares during the last quarter. RPg Family Wealth Advisory LLC acquired a new stake in shares of Koninklijke Philips in the third quarter valued at approximately $107,000. Cable Hill Partners LLC acquired a new stake in shares of Koninklijke Philips in the third quarter valued at approximately $203,000. Finally, Endowment Wealth Management Inc. acquired a new stake in shares of Koninklijke Philips in the third quarter valued at approximately $205,000. Institutional investors own 13.67% of the company’s stock.

Koninklijke Philips Price Performance

PHG opened at $26.04 on Friday. The company has a fifty day moving average price of $26.37 and a two-hundred day moving average price of $28.06. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.74 and a current ratio of 1.23. Koninklijke Philips has a 52 week low of $19.75 and a 52 week high of $32.91. The firm has a market capitalization of $24.47 billion, a PE ratio of -30.99, a P/E/G ratio of 0.82 and a beta of 0.77.

Koninklijke Philips (NYSE:PHG) last released its earnings results on Wednesday, February 19th. The technology company reported $0.54 EPS for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.01). Koninklijke Philips had a positive return on equity of 10.85% and a negative net margin of 3.88%. The business had revenue of $5.38 billion for the quarter, compared to analyst estimates of $5.10 billion. As a group, analysts anticipate that Koninklijke Philips will post 1.63 earnings per share for the current year.

Koninklijke Philips Cuts Dividend

The firm also recently announced an annual dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 13th will be issued a dividend of $0.886 per share. This represents a yield of 2.9%. The ex-dividend date is Tuesday, May 13th. Koninklijke Philips’s dividend payout ratio is presently -89.29%.

Analysts Set New Price Targets

A number of analysts recently weighed in on PHG shares. StockNews.com lowered shares of Koninklijke Philips from a “buy” rating to a “hold” rating in a report on Friday. UBS Group raised shares of Koninklijke Philips from a “neutral” rating to a “buy” rating in a report on Thursday, February 20th. Finally, BNP Paribas raised shares of Koninklijke Philips from a “neutral” rating to an “outperform” rating in a report on Tuesday. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.